Company intelligence / Profile preview

Medtrade

Ownership: Private
Development stage: Commercial

Overview

Medtrade has developed CELOX technology, a line of haemostatic devices that have been delivered to frontline medics worldwide—including over one million units to Ukraine—and are now expanding into obstetric applications with the CELOX PPH Uterine Haemostatic Tamponade. Clinical trials for internal surgical use of Celox have been completed, with results being analyzed. The company reports strong sales growth and global adoption across military, emergency response, and hospital settings.

Therapeutic areas: Infectious DiseasesWomen's HealthHematology
Modalities: DeviceBiologic
Industry: Therapeutic Medical Devices

Partnerships

KEBOMED Europe AG

Beyond the preview

Go deeper on Medtrade.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medtrade.

Explore the full profile